Xiao-He Ren
Overview
Explore the profile of Xiao-He Ren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
84
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ren X, Guo T, Xu M, Huang Y, Liao X, Qi L, et al.
Adv Healthc Mater
. 2024 Oct;
14(1):e2401223.
PMID: 39440615
Cancer immunotherapy, which aims to eliminate cancer immunosuppression and reactivate anticancer immunity, holds great promise in oncology treatments. However, it is challenging to accurately study the efficacy of immunotherapy based...
2.
Han D, Ren X, He X, Chen X, Pang X, Cheng S
ACS Biomater Sci Eng
. 2023 Sep;
9(10):5832-5842.
PMID: 37679307
Identification of diverse biomarkers in heterogenic circulating malignant cells (CMCs) such as circulating tumor cells (CTCs) and circulating tumor endothelial cells (CTECs) has crucial significance in tumor diagnosis. However, it...
3.
Han D, He X, Huang Y, Gao M, Guo T, Ren X, et al.
Adv Sci (Weinh)
. 2023 Aug;
10(29):e2303309.
PMID: 37590231
Cell fusion plays a critical role in cancer progression and metastasis. However, effective modulation of the cell fusion behavior and timely evaluation on the cell fusion to provide accurate information...
4.
Han D, Ren X, Liao X, He X, Guo T, Chen X, et al.
Nano Lett
. 2023 Apr;
23(9):3678-3686.
PMID: 37052638
Identification of cancer metastatic sites is of importance for adjusting therapeutic interventions and treatment choice. However, identifying the location of metastatic lesions with easy accessibility and high safety is challenging....
5.
Xu C, Ren X, Han D, Peng Y, Lei J, Yu L, et al.
Anal Chem
. 2022 Dec;
94(49):17334-17340.
PMID: 36456915
Cell-cell fusion studies provide an experimental platform for evaluating disease progression and investigating cell infection. However, to realize sensitive and quantitative detection on cell-cell fusion is still a challenge. Herein,...
6.
Ren X, Han D, He X, Guo T, Chen X, Pang X, et al.
Adv Healthc Mater
. 2022 Nov;
12(4):e2202155.
PMID: 36333906
Cancer heterogeneity plays a vital part in cancer resistance and metastasis. To provide a reliable approach to exert a therapy action and evaluate its efficiency in heterogeneous cancer cells, a...
7.
Che Y, Ren X, Wang Z, Wu Q, Xing K, Zhang M, et al.
Adv Mater
. 2022 Oct;
35(16):e2207227.
PMID: 36314402
The chronic rejection responses and side effects of the systematic administration of immunosuppressants are the main obstacles to heart allograft and patient survival. The development of xenotransplantation also urgently requires...
8.
Mu Y, Ren X, Han D, Guan Y, Liu P, Cheng S, et al.
Pharmaceutics
. 2022 Jul;
14(7).
PMID: 35890334
Chronic hepatitis B is a critical cause of many serious liver diseases such as hepatocellular carcinoma (HCC). The main challenges in hepatitis B treatment include the rebound of hepatitis B...
9.
Xu C, He X, Ren X, Han D, Cheng S
Anal Chem
. 2022 Jul;
94(30):10610-10616.
PMID: 35856393
To study the heterogeneity of circulating tumor cells (CTCs) is of crucial importance to analyze cancer progression and metastasis. However, in situ detection of highly heterogeneous CTCs in peripheral blood...
10.
Chen Q, Shen M, Ren X, Zhu S, Shang J, Liu W, et al.
J Mater Chem B
. 2022 Jun;
10(27):5154-5164.
PMID: 35666635
Tumor-triggered targeting ammonium bicarbonate (TTABC) liposomes were proposed to improve the uptake of ammonium bicarbonate (ABC) liposomes in tumor cells and retain their long circulation in our previous study. However,...